OptoWavePro | Near natural hearing restoration through waveguide-based optical cochlear implants

Summary
OptoWavePro aims to develop a human prototype for an optical stimulator for optogenetic hearing restoration in individuals with profound hearing impairment. Leveraging optogenetics and biomedical engineering, we strive to restore near-natural hearing by precise optogenetic control of the auditory nerve for which we obtained preclinical proof. Our multidisciplinary team will design, fabricate, and validate the stimulator, emphasizing safety, efficacy, and regulatory compliance. Preclinical studies will validate efficacy, reliability, and biocompatibility, to prepare clinical trials.
The OptoWavePro consortium will introduce a new paradigm of integrating arrays of laser diodes, micro-lenses and polymer-based waveguides on minimal space for the optical stimulator to meet the required form factor of the optical cochlear implant. We will facilitate the upscaling of optical stimulation channels by combining custom-designed and complementary elements with lateral channel pitches of only 100 micrometers throughout the optical pathway. Our biomedical engineering focusses on achieving efficacy and safety by housing all electronic components in a hermetically sealed titanium housing with optical feedthroughs and efficient and stable light in- and outcoupling of the waveguide array. The optical cochlear implant has the potential to revolutionize hearing restoration, merging scientific innovation with clinical impact, and transforming lives globally.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/101158920
Start date: 01-04-2024
End date: 31-03-2027
Total budget - Public funding: 2 499 983,75 Euro - 2 499 983,00 Euro
Cordis data

Original description

OptoWavePro aims to develop a human prototype for an optical stimulator for optogenetic hearing restoration in individuals with profound hearing impairment. Leveraging optogenetics and biomedical engineering, we strive to restore near-natural hearing by precise optogenetic control of the auditory nerve for which we obtained preclinical proof. Our multidisciplinary team will design, fabricate, and validate the stimulator, emphasizing safety, efficacy, and regulatory compliance. Preclinical studies will validate efficacy, reliability, and biocompatibility, to prepare clinical trials.
The OptoWavePro consortium will introduce a new paradigm of integrating arrays of laser diodes, micro-lenses and polymer-based waveguides on minimal space for the optical stimulator to meet the required form factor of the optical cochlear implant. We will facilitate the upscaling of optical stimulation channels by combining custom-designed and complementary elements with lateral channel pitches of only 100 micrometers throughout the optical pathway. Our biomedical engineering focusses on achieving efficacy and safety by housing all electronic components in a hermetically sealed titanium housing with optical feedthroughs and efficient and stable light in- and outcoupling of the waveguide array. The optical cochlear implant has the potential to revolutionize hearing restoration, merging scientific innovation with clinical impact, and transforming lives globally.

Status

SIGNED

Call topic

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01

Update Date

15-11-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon Europe
HORIZON.3 Innovative Europe
HORIZON.3.1 The European Innovation Council (EIC)
HORIZON.3.1.0 Cross-cutting call topics
HORIZON-EIC-2023-TRANSITION-01
HORIZON-EIC-2023-TRANSITIONCHALLENGES-01 EIC Transition Challenge: Full scale Micro-Nano-Bio devices for medical and medical research applications